FEIBA: A Prohemostatic Agent

被引：18

作者：

Cromwell, Caroline ^{[1
]}

Aledort, Louis M. ^{[1
]}

机构：

[1] Mt Sinai Sch Med, Dept Med, Div Hematol Oncol, New York, NY 10029 USA

来源：

SEMINARS IN THROMBOSIS AND HEMOSTASIS | 2012年 / 38卷 / 03期

关键词：

inhibitors; hemophilia; factor eight inhibitor bypassing activity; thrombosis; FACTOR-VIII-INHIBITOR; PROTHROMBIN COMPLEX CONCENTRATE; THROMBIN GENERATION TEST; FACTOR-IX INHIBITORS; BYPASSING AGENTS; HEMOPHILIA-A; MYOCARDIAL-INFARCTION; PATIENT; SURGERY; SAFETY;

D O I：

10.1055/s-0032-1309286

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Factor eight inhibitor bypassing activity (FEIBA), Anti-Inhibitor Coagulation Complex has been used for over 30 years in hemophiliac patients with inhibitors. The history of its use is reviewed here, including issues related to thrombosis, efficacy, and comparison to alternative bypassing agents. The need for surrogate assays to monitor effective hemostasis with the use of FEIBA remains.

引用

页码：265 / 267

页数：3

共 24 条

[21]

Negrier C, 1997, THROMB HAEMOSTASIS, V77, P1113

[22]

SCHIMPF K, 1982, LANCET, V2, P1043

[23] FEIBA®:: mode of action [J].

Turecek, PL ;

Váradi, K ;

Gritsch, H ;

Schwarz, HP .

HAEMOPHILIA, 2004, 10 :3-9

[24] Factor VIII inhibitor-bypassing agents act by inducing thrombin generation and can be monitored by a thrombin generation assay [J].

Turecek, PL ;

Váradi, K ;

Keil, B ;

Negrier, C ;

Berntorp, E ;

Astermark, J ;

Bordet, JC ;

Morfini, M ;

Linari, S ;

Schwarz, HP .

PATHOPHYSIOLOGY OF HAEMOSTASIS AND THROMBOSIS, 2003, 33 (01) :16-22

← 1 2 3 →